P2RX7 and age-related macular degeneration: A recent retrospective clinical study found no statistically significant differences in the prevalence of early‐to‐intermediate AMD, geographic atrophy, or exudative AMD between HIV patients who utilized P2X7 receptor inhibitors and those who did not [3].